Figure 1 and Figure 2 show the estimated PFS and OS curves of patients with advanced RCC treated with IO combination therapy according to their sPD-1, sPD-L1, sPD-L2, and sLAG-3 levels, respectively. A high sPD-L2 level was a predictor of significantly worse PFS (p = 0.0027) and OS (p = 0.0363) than a low sPD-L2 level. On the other hand, a low sLAG-3 level was a predictor of significantly worse PFS (p = 0.0030) than a high sLAG-3 level. The gene discussed is LAG3; the disease is renal cell carcinoma.